Effect of Metformin Treatment On Multiple Cytokines And Oxidative Stress In Type 2 Diabetes Mellitus Patients
Main Article Content
Abstract
Objective: To investigate the effect of metformin treatment on multiple cytokines and oxidative stress in type 2 diabetes mellitus (T2DM) patients.
Methods: The 130 newly diagnosed T2DM patients were randomly divided into an observation group and a control group, with 40 cases in each group. The patients in the control group were treated conventionally, and the patients in the observation group were given 500 mg of metformin twice a day after meals for 3 months. The ankle-brachial index, oxidative stress index level, inflammatory cytokine level, pain degree (VAS score), clinical symptom scores and treatment effect were compared between the two groups before and after treatment.
Results: The results showed that the clinical symptom scores were significantly lower, and the ABI index was significantly higher in the observation group after treatment than those in the control group and before treatment (P < 0.05). The levels of isoprostaglandin F2α and oxidized low-density lipoprotein were lower and the superoxide dismutase level was higher in the observation group after treatment than those in the control group and before treatment (P < 0.05). After treatment, the pain degree score in the observation group was lower than that in the control group (P < 0.05). The total effective rate in the observation group was 97.50%, which was higher than the 72.50% in the control group.
Conclusion: Metformin treatment can significantly improve the clinical symptoms of T2DM patients and sufficiently reduce the level of oxidative stress, while has no significant effect on the inflammatory cytokines in patients.
Article Details
References
[1] Jadad, A.R., et al., Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials, 1996. 17(1): p. 1-12.
[2] Downs, S.H. and N. Black, The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health, 1998. 52(6): p. 377-84.
[3] Higgins, J.P., et al., Measuring inconsistency in meta-analyses. Bmj, 2003. 327(7414): p. 557-60.
[4] Kahn, S.E., et al., Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med, 2006. 355(23): p. 2427-43.
[5] Economic costs of diabetes in the U.S. In 2007. Diabetes Care, 2008. 31(3): p. 596-615.
[6] Owens, D.K., et al., AHRQ series paper 5: grading the strength of a body of evidence when comparing medical interventions--agency for healthcare research and quality and the effective health-care program. J Clin Epidemiol, 2010. 63(5): p. 513-23.
[7] Schramm, T.K., et al., Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J, 2011. 32(15): p. 1900-8.
[8] Apostolova, N., et al., Mechanisms of action of metformin in type 2 diabetes: Effects on mitochondria and leukocyte-endothelium interactions. Redox Biol, 2020. 34: p. 101517.
[9] Sanchez-Rangel, E. and S.E. Inzucchi, Metformin: clinical use in type 2 diabetes. Diabetologia, 2017. 60(9): p. 1586-1593.
[10] Pantalone, K.M., et al., Increase in overall mortality risk in patients with type 2 diabetes receiving glipizide, glyburide or glimepiride monotherapy versus metformin: a retrospective analysis. Diabetes Obes Metab, 2012. 14(9): p. 803-9.
[11] Karcioglu, O., et al., A systematic review of the pain scales in adults: Which to use? Am J Emerg Med, 2018. 36(4): p. 707-714.
[12] Inzucchi, S.E., et al., Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care, 2012. 35(6): p. 1364-79.
[13] Yu, S., et al., Chemerin and apelin are positively correlated with inflammation in obese type 2 diabetic patients. Chin Med J (Engl), 2012. 125(19): p. 3440-4.
[14] Hong, J., et al., Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes Care, 2013. 36(5): p. 1304-11.
[15] Wheeler, S., et al., Mortality among veterans with type 2 diabetes initiating metformin, sulfonylurea or rosiglitazone monotherapy. Diabetologia, 2013. 56(9): p. 1934-43.
[16] Cornell, J.E., et al., Random-effects meta-analysis of inconsistent effects: a time for change. Ann Intern Med, 2014. 160(4): p. 267-70.
[17] Inzucchi, S.E., et al., Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 2015. 38(1): p. 140-9.
[18] Gu, S., et al., Comparison of glucose lowering effect of metformin and acarbose in type 2 diabetes mellitus: a meta-analysis. PLoS One, 2015. 10(5): p. e0126704.
[19] Maruthur, N.M., et al., Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes: A Systematic Review and Meta-analysis. Ann Intern Med, 2016. 164(11): p. 740-51.
[20] Pan, H.Z., et al., Oxidative damage to DNA and its relationship with diabetic complications. Biomed Environ Sci, 2007. 20(2): p. 160-3.
[21] Lee, C.B., et al., The Relationship between the Gut Microbiome and Metformin as a Key for Treating Type 2 Diabetes Mellitus. Int J Mol Sci, 2021. 22(7).
[22] Wang, J.S., et al., Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison. Clin Ther, 2011. 33(12): p. 1932-42.
[23] Baeza-Flores, G.D.C., et al., Metformin: A Prospective Alternative for the Treatment of Chronic Pain. Front Pharmacol, 2020. 11: p. 558474.
[24] Kułaczkowska, Z.M., et al., Metformin in patients with type 2 diabetes mellitus and heart failure: a review. Endokrynol Pol, 2021. 72(2): p. 163-170.